Mina Sooch
Strategic Adviser Cirius Therapeutics
Seminars
Thursday 16th July 2026
Reprogramming Mitochondrial Metabolism to Deliver Muscle-Preserving Efficacy in a Scalable Daily Pill to Offer Effective Alternative Treatment
2:10 pm
- Engineering next-generation MPC-inhibitor platforms to bypass the gastric proteolytic barrier, utilizing selective mitochondrial reprogramming to deliver metabolic benefits that achieve muscle-preserving efficacy comparable to lean-body controls while augmenting the weight-loss power of high-dose injectables
- Implementing a “Synergy-First” clinical strategy where patients utilize oral MPC inhibitors alongside injectable induction or as a long-term maintenance continuum, allowing companies to protect market share by offering metabolic-correcting, needle-free options for life-long weight stability and the prevention of post-treatment regain
- Optimizing large-scale synthetic small-molecule manufacturing processes to bypass the global constraints of “cold-chain” distribution and specialized injection hardware, ensuring consistent drug availability to meet the projected 40%+ annual growth in global patient demand for high-quality, body-composition-focused obesity care
